RSV Vaccine for Babies, Toddlers: The FDA approved the 1st respiratory syncytial virus (RSV) vaccine for babies and toddlers. Beyfortus (nirsevimab-alip) is approved for the prevention of RSV lower respiratory tract disease in children <24 months of age who remain vulnerable to severe RSV disease through their 2nd RSV season. Read the FDA news release.
The CDC recommends 1 dose of nirsevimab for all infants <8 months, born during – or entering – their 1st RSV season, typically fall through spring. For a small group of children ages 8 - 19 months who are at increased risk of severe RSV disease, such as children who are severely immunocompromised, a dose is recommended in their 2nd season. Read the CDC news release.
1st OTC for Postpartum Depression: The FDA approved Zurzuvae (zuranolone), the 1st oral medication indicated to treat postpartum depression in adults. Read the FDA news release.